Vitura Health Limited · ASX:VIT
Vitura Health — Investor Presentation (February 2026)
23 slides from Vitura Health's investor presentation, Feb 25, 2026
Slide 1: H1 FY2026 Results Investor Webinar
H1 FY2026 RESULTS INVESTOR WEBINAR 26 FEBRUARY 2026 9AM (AEDT) Robert Iervasi – Non-Executive Chair Shane Tanner – Executive Director Ryan Tattle – Chief Revenue Officer Andrew Cook – Chief Financial Officer COMMERCIAL IN CONFIDENCE 1
Slide 2: Agenda
AGENDA • Company Overview • H1 FY2026 Highlights, Financials & Leadership Update • Operational Overview • Conclusion Vitura Health Limited 2
Slide 3: Company Overview
COMPANY OVERVIEW | .
Slide 4: Vitura's unique digital health ecosystem
Vitura’s unique digital health ecosystem • Fully integrated end-to-end digital health platform. • Distribution, logistics and route-to-market services for licensed wholesale supply of products including: - Medicinal Cannabis - Therapeutic Nicotine Vaping Products - MDMA and Psilocybin • All managed
Slide 5: Vitura Overview – Operational Segmentation
Vitura Overview – Operational Segmentation General Practice Clinic Specialty & JV Clinics Marketplace Products Vitura Health Limited 5
Slide 6: Vision & Mission
Vision & Mission Vision // To lead the future of healthcare access in specialty and emerging therapies. Mission // Build a connected ecosystem of patients, clinicians, pharmacies and suppliers through a seamless platform that delivers trusted access to specialty and emerging therapies. Vitura Health
Slide 7: H1 FY2026 Highlights, Financials & Leadership Update
H1 FY2026 Highlights, Financials & Leadership Update
Slide 8: H1 FY 2026 Financial Results - Summary
H1 FY 2026 Financial Results - Summary A$M H1 FY2026 H1 FY2025 Operating revenue 67.9 62.7 Normalised EBITDA 1.9 4.6 Net Profit After Tax (NPAT) (1.0) 1.6 Normalised NPAT (0.4) 2.2 Normalised Earnings Per Share (Cents) (0.05) 0.37 Notes: Normalised for costs relating to acquisitions and the successf
Slide 9: H1 FY 2026 Financial Results - Highlights
H1 FY 2026 Financial Results - Highlights Key Points • Strong revenue growth o H1 FY2026 revenue $67.9m - UP 8.3% vs PCP, driven from sales and distribution of medicinal cannabis and Nicotine Vaping Products (NVPs). o Burleigh Heads Cannabis (BHC) sold a total of 507,799 units via the Canview platfo
Slide 10: H1 FY 2026 Financial Results - Highlights
H1 FY 2026 Financial Results - Highlights Key Points • Doctors on Demand growth o 21% growth in revenue compared to PCP. o Total consultation numbers up 15% year on year, o Afterhours consultations up by almost 32%, driven largely by B2C patients. • Candor adds to patient numbers o Integration adds
Slide 11: H1 FY2026 Financial Results - Highlights
H1 FY 2026 Financial Results - Highlights Key Points • Challenging H1 but plans in place to quickly improve in H2 and beyond. o Normalised EBITDA $1.9M vs $4.6M in PCP. o Normalised loss after income tax - NPAT - ($0.4M) vs PCP profit of $2.2M. o Driven largely by market-wide compression of medicina
Slide 12: H1 FY2026 Cashflows
H1 FY2026 Cashflows A$M – Cashflows used in operating activities H1 FY2026 H1 FY2025 Receipts from customers 71.0 68.2 Payments made to suppliers and employees (72.0) (68.7) Income tax (paid) / refunded, net (0.1) 0.4 Net Interest paid (0.3) (0.1) Net cash flows used in operating activities (1.4) (0
Slide 13: H1 FY2026 revenue and earnings
H1 FY2026 revenue and earnings Total revenue for H1 FY2026 of $67.9M • Revenues up 8.3% vs PCP and 10.8% vs H2 FY2025. Comprising: • Strong unit sales with a 10.6% increase on • Sales and distribution: $52M – UP 4% YOY PCP via the Canview platform. • Clinics and service: $15.9M – UP 25% YOY • Howeve
Slide 14: Operational Overview & Immediate Priorities
OPERATIONAL OVERVIEW & IMMEDIATE PRIORITIES
Slide 15: Focus on Accelerated Execution and Improved Results
Focus on Accelerated Execution and Improved Results. Key Points o Leadership transition announced in January 2026. o Chief Revenue Officer Ryan Tattle assumed responsibility for day-to-day management. o Non-Executive Director Shane Tanner assumed interim Executive Director Role to provide extra supp
Slide 16: Strategy Remains - Accelerated Execution Commenced
Strategy Remains - Accelerated Execution Commenced STRENGTHEN EXPAND STRENGTHEN TEAM AND CUSTOMER TECHNOLOGY FINANCIAL MARKET COMPANY AND MARKET ENHANCEMENT IMPROVEMENT POSITION CULTURE BASE Vitura Health Limited 16
Slide 17: Accelerated Execution Commenced – Candor & Releaf
Accelerated Execution Commenced – Candor & Releaf • Vitura acquired Candor Medical, one of Australia’s leading medicinal cannabis clinics, in February 2025. • An additional 15,000 active patients through a fully integrated digital platform. We will acquire & retain patients via: • Reduced pricing fo
Slide 18: Accelerated Execution Commenced – Doctors on Demand
Acquisitions Accelerated Driving Growth Execution – Doctors Commenced on Demand - Doctors on Demand • 24/7 nationwide GP telehealth services, 365 days a year. • Continue revenue strong growth in H2 FY2026 - (Up 21% vs PCP in H1 FY2026). • Continue growing consultation numbers in H2 FY2026 - (Up 15%
Slide 19: Accelerated Execution Commenced – Operational Expenditure
Accelerated Execution Commenced – Operational Expenditure • Restructure of roles/scopes at executive and senior manager levels. • Recent 10% reduction of total OPEX base of circa $28m already actioned. • Cost reduction initiatives and efficiency gains to flow through in H2 2026 and beyond. Vitura He
Slide 20: Accelerated Execution Commenced - Canview
Accelerated Execution Commenced - Canview • Canview is Vitura’s centralised technology platform. • Almost 508,000 medicinal cannabis units distributed in H1 FY2026 – UP 10.2% vs PCP • Around 760 (Vitura and competitor) products and 88 brands now available on Canview – and growing. • Registered pharm
Slide 21: Conclusion
Conclusion • New leadership already making a difference in terms of sales growth and cost reductions. • Strong double-digit revenue growth expected over next two years commencing in the current month. • Maintain current gross margin levels into the immediate future. • Canview platform continues to b
Slide 22: Disclaimer applying to this Presentation
Disclaimer applying to this Presentation The following disclaimer applies to this presentation (Presentation) You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation h
Slide 23: Vitura Health Limited
vitura.com.au VITURA HEALTH LIMITED ASX : VIT info@vitura.com.au 1300 799 491
Vitura Health — Investor Presentation (February 2026) on 6ix